Neural stem cell-derived exosome as a nano-sized carrier for BDNF delivery to a rat model of ischemic stroke

Zhu, Zhihan; Feng, Jia; Waqas, Ahmed; Zhang, Guilong; Wang, Hong; Lin, Chaoqun; Chen, Wang-Hao; Chen, Lukui

doi:10.4103/1673-5374.346466

Cited by 56 publications

(28 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BDNF was loaded into NSC‐Exos to construct the engineered BDNF‐HNSC‐Exos. In the MCAO rat model, BDNF‐HNSC‐Exos can inhibit microglial activation, promote endogenous NSC differentiation in neurons, inhibit the inflammatory response, create a suitable microenvironment for nerve regeneration, and alleviate NSC stress injury 287 . Neuronal exosomes loaded with quercetin target ischemic brain tissue, improve neuronal survival, and reduce I/R damage by scavenging ROS production 288 .…”

Section: Exosomes In Neuropsychiatric Disordersmentioning

confidence: 99%

Exosomes in brain diseases: Pathogenesis and therapeutic targets

Pang

et al. 2023

MedComm

View full text Add to dashboard Cite

Exosomes are extracellular vesicles with diameters of about 100 nm that are naturally secreted by cells into body fluids. They are derived from endosomes and are wrapped in lipid membranes. Exosomes are involved in intracellular metabolism and intercellular communication. They contain nucleic acids, proteins, lipids, and metabolites from the cell microenvironment and cytoplasm. The contents of exosomes can reflect their cells’ origin and allow the observation of tissue changes and cell states under disease conditions. Naturally derived exosomes have specific biomolecules that act as the “fingerprint” of the parent cells, and the contents changed under pathological conditions can be used as biomarkers for disease diagnosis. Exosomes have low immunogenicity, are small in size, and can cross the blood–brain barrier. These characteristics make exosomes unique as engineering carriers. They can incorporate therapeutic drugs and achieve targeted drug delivery. Exosomes as carriers for targeted disease therapy are still in their infancy, but exosome engineering provides a new perspective for cell‐free disease therapy. This review discussed exosomes and their relationship with the occurrence and treatment of some neuropsychiatric diseases. In addition, future applications of exosomes in the diagnosis and treatment of neuropsychiatric disorders were evaluated in this review.

show abstract

Section: Exosomes In Neuropsychiatric Disordersmentioning

confidence: 99%

Exosomes in brain diseases: Pathogenesis and therapeutic targets

Pang

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…Inspiringly, NSC‐EVs preloaded with potential drugs for ischemia/hypoxia exert promising therapeutic effects on in vitro and in vivo stroke models. For instance, NSC‐EVs loaded with BDNF alleviated neurological deficits and brain damage in MCAO mice post‐stereo‐tactical insertion, accompanied by inhibited microglial activation and promoted neurogenesis 194 . Besides, surface engineered NSC‐EVs have also been applied to the treatment of stroke.…”

Section: Nsc‐evs As a Drug Delivery Platform For Treating Neurologica...mentioning

confidence: 99%

“…For instance, NSC-EVs loaded with BDNF alleviated neurological deficits and brain damage in MCAO mice post-stereo-tactical insertion, accompanied by inhibited microglial activation and promoted neurogenesis. 194 Besides, surface engineered NSC-EVs have also been applied to the treatment of stroke. Tian et al 23 constructed a recombinant fusion protein that contained arginine-glycine-aspartate (RGD)-4C peptide (ACDCRGDCFC) fused with PS binding domain of lactadherin (C1C2).…”

Section: Nsc-evs As a Drug Delivery Platform For Treating Neurologica...mentioning

confidence: 99%

Neural stem/progenitor cell‐derived extracellular vesicles: A novel therapy for neurological diseases and beyond

Zhu

Wang

et al. 2023

MedComm

View full text Add to dashboard Cite

As bilayer lipid membrane vesicles secreted by neural stem/progenitor cells (NSCs), NSC-derived extracellular vesicles (NSC-EVs) have attracted growing attention for their promising potential to serve as novel therapeutic agents in treatment of neurological diseases due to their unique physicochemical characteristics and biological functions. NSC-EVs exhibit advantages such as stable physical and chemical properties, low immunogenicity, and high penetration capacity to cross blood-brain barrier to avoid predicaments of the clinical applications of NSCs that include autoimmune responses, ethical/religious concerns, and the problematic logistics of acquiring fetal tissues. More importantly, NSC-EVs inherit excellent neuroprotective and neuroregenerative potential and immunomodulatory capabilities from parent cells, and display outstanding therapeutic effects on mitigating behavioral alterations and pathological phenotypes of patients or animals with neurological diseases. In this review, we first comprehensively summarize the progress in functional research and application of NSC-EVs in different neurological diseases, including neurodegenerative diseases, acute neurological diseases, dementia/cognitive dysfunction, and peripheral diseases. Next, we provide our thoughts on current limitations/concerns as well as tremendous potential of NSC-EVs in clinical applications. Last, we discuss future directions of further investigations on NSC-EVs and their probable applications in both basic and clinical research.

show abstract

“…Human neural stem cell-derived exosomes engineered with BDNF (BDNF-hNSC-Exo) markedly enhance cell survival in an ischemic stroke model in vitro and in vivo (Zhu et al, 2023). While further preclinical evaluation is required, the discovery of these nanocarriers of BDNF has increased the efficiency of BDNF delivery in vivo, which will pave the way for establishing BDNF as a powerful therapeutic for the treatment of demyelinating diseases such as multiple sclerosis in the future.…”

Section: Improving Bdnf Delivery Via Nanocarriersmentioning

confidence: 99%

“…Recently, the exosome is emerging as a promising drug delivery vehicle, due to its nanoscale (30–200 nm in size), biocompatibility, high circulation stability, and biological barrier permeability (Chinnappan et al, 2020; Meng et al, 2020). Human neural stem cell‐derived exosomes engineered with BDNF (BDNF‐hNSC‐Exo) markedly enhance cell survival in an ischemic stroke model in vitro and in vivo (Zhu et al, 2023). While further preclinical evaluation is required, the discovery of these nanocarriers of BDNF has increased the efficiency of BDNF delivery in vivo, which will pave the way for establishing BDNF as a powerful therapeutic for the treatment of demyelinating diseases such as multiple sclerosis in the future.…”

Section: Bdnf‐based Myelin Repair Strategies: Replacement and Revivalmentioning

confidence: 99%

Thirty years of BDNF study in central myelination: From biology to therapy

Xiao

2023

Journal of Neurochemistry

View full text Add to dashboard Cite

Being the highest expressed neurotrophin in the mammalian brain, the brain‐derived neurotrophic factor (BDNF) is essential to neural development and plasticity in both health and diseases. Following the discovery of BDNF by Yves‐Alain Barde in 1982, the main feature of BDNF's activity in myelination was first described by Cellerino et al. in 1997. Since then, genetic manipulation of the BDNF‐encoding gene and its receptors in murine models has revealed the contribution of BDNF to the myelinating process in the central nervous system (CNS). The series of BDNF or receptor mouse mutants as well as the BDNF polymorphism in humans have provided new insights into the roles that BDNF signaling plays in myelination in a complex manner. 2024 marks the 30th year of BDNF's research in myelination. Here, we share our perspective on the 30‐year history of BDNF in the field of CNS myelination from phenotyping to therapeutic development, focusing on genetic evidence regarding the mechanism by which BDNF regulates myelin formation and repair in the CNS. This review also discusses the current hypotheses of BDNF's action on CNS myelination: axonal‐ and oligodendroglial‐driven mechanisms, which may be ultimately activity‐dependent. Last, this review raises the challenges and opportunities of developing BDNF‐based therapies for neurodegenerative diseases, opening unanswered questions for future investigation.image

show abstract

Neural stem cell-derived exosome as a nano-sized carrier for BDNF delivery to a rat model of ischemic stroke

Cited by 56 publications

References 43 publications

Exosomes in brain diseases: Pathogenesis and therapeutic targets

Exosomes in brain diseases: Pathogenesis and therapeutic targets

Neural stem/progenitor cell‐derived extracellular vesicles: A novel therapy for neurological diseases and beyond

Thirty years of BDNF study in central myelination: From biology to therapy

Contact Info

Product

Resources

About